In a phase III trial involving more than 1,200 patients with follicular lymphoma, obinutuzumab plus chemotherapy reduced the risk of disease progression, relapse, or death by 34% compared with rituximab plus chemotherapy. However, patients receiving obinutuzumab experienced more serious side effects than those receiving rituximab.
http://ift.tt/2ArtmRC
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου